Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – Research analysts at Zacks Investment Research decreased their Q2 2017 earnings per share estimates for Brainstorm Cell Therapeutics in a research report issued on Tuesday. Zacks Investment Research analyst D. Bautz now expects that the biotechnology company will post earnings of ($0.10) per share for the quarter, down from their previous estimate of ($0.06). Zacks Investment Research also issued estimates for Brainstorm Cell Therapeutics’ Q3 2017 earnings at ($0.10) EPS and FY2017 earnings at ($0.38) EPS.
Separately, Maxim Group set a $8.00 price objective on shares of Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research report on Wednesday, April 19th.
Shares of Brainstorm Cell Therapeutics (NASDAQ BCLI) opened at 4.42 on Friday. Brainstorm Cell Therapeutics has a one year low of $2.06 and a one year high of $5.10. The firm has a 50 day moving average of $4.08 and a 200 day moving average of $3.52. The stock’s market cap is $82.81 million.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.20.
Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Brainstorm Cell Therapeutics by 10.0% in the first quarter. Vanguard Group Inc. now owns 639,444 shares of the biotechnology company’s stock valued at $2,717,000 after buying an additional 58,287 shares during the period. Perceptive Advisors LLC acquired a new position in Brainstorm Cell Therapeutics during the fourth quarter valued at $1,016,000. Geode Capital Management LLC raised its position in Brainstorm Cell Therapeutics by 19.7% in the first quarter. Geode Capital Management LLC now owns 73,366 shares of the biotechnology company’s stock valued at $311,000 after buying an additional 12,097 shares during the period. Finally, KCG Holdings Inc. raised its position in Brainstorm Cell Therapeutics by 4.6% in the first quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 1,820 shares during the period. Institutional investors own 8.02% of the company’s stock.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2231158/zacks-investment-research-comments-on-brainstorm-cell-therapeutics-inc-s-q2-2017-earnings-bcli.html
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.